(VTHR) Russell 3000 Shares - Overview
Etf: ETF, Index, Stocks
Dividends
| Dividend Yield | 1.17% |
| Yield on Cost 5y | 1.89% |
| Yield CAGR 5y | 6.61% |
| Payout Consistency | 99.2% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 15.3% |
| Relative Tail Risk | 4.95% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.60 |
| Alpha | -0.34 |
| Character TTM | |
|---|---|
| Beta | 0.975 |
| Beta Downside | 0.976 |
| Drawdowns 3y | |
|---|---|
| Max DD | 19.36% |
| CAGR/Max DD | 1.04 |
Description: VTHR Russell 3000 Shares January 11, 2026
The Vanguard Russell 3000 Index Fund ETF (NASDAQ: VTHR) seeks to replicate the Russell 3000® Index, which covers roughly 98 % of the U.S. equity market by holding the 3,000 largest U.S. companies in proportion to their index weights. The fund’s strategy is a pure indexing approach-essentially buying the same stocks in the same weights as the benchmark-so its performance should closely track the index, less fees. Because it holds a very large number of securities, the fund is classified as “non-diversified” under SEC rules, a technical label that does not imply concentration risk.
Key metrics as of the latest filing (Q4 2025) show an expense ratio of 0.03 %, a total net asset value (NAV) of about $2.1 billion, and an average daily trading volume of roughly 150,000 shares, indicating strong liquidity. The fund’s performance is highly correlated (≈ 0.99) with the broader U.S. market, making macro-economic drivers such as GDP growth, Federal Reserve policy, and corporate earnings trends the primary determinants of returns. Sector exposure mirrors the market composition, with technology (~27 %) and health care (~14 %) being the largest weightings, so sector-specific shocks (e.g., semiconductor supply constraints or biotech regulatory changes) can materially affect short-term performance.
If you want a deeper, data-driven view of how VTHR behaves under different market regimes, ValueRay’s analytical tools can help you model scenario outcomes without bias.
What is the price of VTHR shares?
Over the past week, the price has changed by +0.16%, over one month by -0.06%, over three months by +3.78% and over the past year by +14.55%.
Is VTHR a buy, sell or hold?
What are the forecasts/targets for the VTHR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 356.7 | 16.7% |
VTHR Fundamental Data Overview February 04, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 4.14b USD (4.14b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 4.14b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 4.14b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 9.51% (E(4.14b)/V(4.14b) * Re(9.51%) + (debt-free company))
Discount Rate = 9.51% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)